伏立诺他联合克拉屈滨和利妥昔单抗治疗复发B细胞非霍奇金淋巴瘤及初治套细胞淋巴瘤的1-2期研究
这项1-2期研究评估了伏立诺他(SAHA)、克拉屈滨和利妥昔单抗(SCR)方案在复发B细胞非霍奇金淋巴瘤和初治套细胞淋巴瘤中的疗效与安全性。1期采用标准3+3剂量递增设计,未观察到剂量限制性毒性,2期推荐伏立诺他剂量为400 mg口服。初治套细胞淋巴瘤客观缓解率达97%(38/39),完全缓解率80%(31/39);复发患者客观缓解率为39%(7/18)。毒性主要为血液学毒性。
要点
- SCR方案在初治套细胞淋巴瘤中客观缓解率97%(38/39),完全缓解率80%(31/39)。
- 1期未观察到剂量限制性毒性,2期伏立诺他推荐剂量为400 mg口服(第1-14天)。
核心结论
- SCR方案在初治套细胞淋巴瘤中显示出高缓解率,在复发非霍奇金淋巴瘤中具有活性,毒性主要为血液学毒性。
研究设计与样本
- 1-2期研究(NCT00764517),1期采用标准3+3剂量递增设计纳入复发患者10例,伏立诺他剂量为200、300和400 mg。
- 2期主要纳入套细胞淋巴瘤患者57例(初治39例,复发10例),主要终点为客观缓解率(完全缓解+部分缓解)。
主要发现
- 1期未观察到剂量限制性毒性,2期伏立诺他推荐剂量为400 mg口服(第1-14天)。
- 初治套细胞淋巴瘤客观缓解率97%(38/39),完全缓解率80%(31/39);复发患者客观缓解率39%(7/18)。
- 毒性主要为血液学毒性。
关键数值与推荐
- 克拉屈滨5 mg/m²静脉注射(第1-5天),利妥昔单抗375 mg/m²静脉注射(第1周期每周4次,之后每月1次),伏立诺他口服每日一次(第1-14天),每28天为一周期,最多6周期。
临床怎么用
- SCR方案可作为初治套细胞淋巴瘤的一种治疗选择,治疗期间需监测血液学毒性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non-Hodgkin lymphomas (NHL) in this phase 1-2 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously (IV) (days 1-5), rituximab 375 mg/m2 IV (weekly 4× for cycle 1 and 1×/month) and vorinostat orally once daily (days 1-14) every 28 days for up to six cycles. Phase 1 included relapsed patients (n = 10) in a standard 3 + 3 dose escalation design (vorinostat: 200, 300 and 400 mg). No dose-limiting toxicities were seen. The phase 2 dose for vorinostat was 400 mg po (days 1-14). The majority of phase 2 patients had mantle cell lymphoma (MCL) (n = 57; 39 previously untreated, 10 relapsed). The primary objective was objective response rate [complete response (CR) + partial response] which was 39% (7/18) in relapsed patients and 97% (38/39) with 80% (31/39) attaining a CR in previously untreated MCL. At a median follow-up of 42 months, median progression-free survival (PFS) and overall survival (OS) for relapsed NHL were 19·5 [95% confidence interval (CI): 2·0-33·0] and 25·0 (95% CI: 12·0-45·0) months respectively. Median PFS for previously untreated MCL was 84·0 months; OS could not be estimated. Toxicities were primarily haematological.
引用
- Spurgeon SE, Sharma K, Claxton DF, et al. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. Br J Haematol. 2019. PMID: 31177537. doi:10.1111/bjh.16008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。